Association of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: a meta-analysis
- PMID: 22010135
- PMCID: PMC3278232
- DOI: 10.1161/CIRCGENETICS.111.960682
Association of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: a meta-analysis
Abstract
Background: Circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin have been associated with variation at the ABO locus. To evaluate these associations and the effect sizes, we performed a meta-analysis with new and previous reported data for polymorphism rs579459.
Methods and results: Compared with major allele homozygotes, heterozygotes and minor allele homozygotes had 4.6% (95% CI, 3.4%-5.8%, P=7.3 × 10(-14)) and 7.2% (95% CI, 4.7%-9.7%, P=1.5 × 10(-8)), respectively, lower soluble intercellular adhesion molecule-1 levels (n=33 671). An allele dose-dependent association also was observed for soluble P-selectin (n=4921) with heterozygotes and minor allele homozygotes having 11.5% (95% CI, 7.2%-15.8%, P=1.7 × 10(-7)) and 18.6% (95% CI, 9.1%-28.1%, P=1.2 × 10(-4)), respectively, lower levels than in major allele homozygotes. A larger effect size, again consistent with an additive genetic model, was seen for soluble E-selectin (n=2860) whose level was 25.6% (95% CI, 19.0%-32.2%, P=2.1 × 10(-14)) lower in heterozygotes and 43.3% (95% CI, 36.9%-49.3%, P=4.3 × 10(-42)) lower in minor allele homozygotes than in major allele homozygotes.
Conclusions: The data support the association of variation at the ABO locus with soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin levels.
Conflict of interest statement
Stefan Kiechl received research grants; TRP188-B12 FWF. Lu Qi received research grants from NIH. Russell P. Tracyreceived other research support from Celera. Paul M Ridker received research grants from AstraZeneca, Novartis, Merck, NHLBI, and NCI. He received other support from Amgen and Celera as well as honorarium from several universities. He has ownership/interest in a patents relate to inflammatory biomarkers. Also, he is a consultant or serves on the advisory board for ISIS, Merck, Vascular Biogenics, and Abbott. Emelia J. Benjamin received research grants; R01HL09257, RC1HL101056, RO1HL102214, RO1AG028321. She also consults or is on advisory committees for NIH and NHLBI.
Figures



Similar articles
-
ABO blood group associations with markers of endothelial dysfunction in the Multi-Ethnic Study of Atherosclerosis.Atherosclerosis. 2016 Aug;251:422-429. doi: 10.1016/j.atherosclerosis.2016.05.049. Epub 2016 Jun 7. Atherosclerosis. 2016. PMID: 27298014 Free PMC article.
-
Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels.Hum Mol Genet. 2010 May 1;19(9):1863-72. doi: 10.1093/hmg/ddq061. Epub 2010 Feb 18. Hum Mol Genet. 2010. PMID: 20167578 Free PMC article.
-
Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin.Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1958-67. doi: 10.1161/ATVBAHA.109.192971. Epub 2009 Sep 3. Arterioscler Thromb Vasc Biol. 2009. PMID: 19729612 Free PMC article.
-
A variant in the ABO gene explains the variation in soluble E-selectin levels-results from dense genotyping in two independent populations.PLoS One. 2012;7(12):e51441. doi: 10.1371/journal.pone.0051441. Epub 2012 Dec 28. PLoS One. 2012. PMID: 23300549 Free PMC article. Clinical Trial.
-
Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes.Hum Mol Genet. 2010 May 1;19(9):1856-62. doi: 10.1093/hmg/ddq057. Epub 2010 Feb 10. Hum Mol Genet. 2010. PMID: 20147318 Free PMC article.
Cited by
-
ABO Blood Groups and Cardiovascular Diseases.Int J Vasc Med. 2012;2012:641917. doi: 10.1155/2012/641917. Epub 2012 Oct 22. Int J Vasc Med. 2012. PMID: 23133757 Free PMC article.
-
Risk Factors, Coronary Severity, Outcome and ABO Blood Group: A Large Chinese Han Cohort Study.Medicine (Baltimore). 2015 Oct;94(43):e1708. doi: 10.1097/MD.0000000000001708. Medicine (Baltimore). 2015. PMID: 26512559 Free PMC article.
-
The ABO Histo-Blood Group and AKI in Critically Ill Patients with Trauma or Sepsis.Clin J Am Soc Nephrol. 2015 Nov 6;10(11):1911-20. doi: 10.2215/CJN.12201214. Epub 2015 Sep 4. Clin J Am Soc Nephrol. 2015. PMID: 26342043 Free PMC article.
-
ABO Blood Group and the Risk and Prognosis of Lymphoma.J Inflamm Res. 2023 Feb 22;16:769-778. doi: 10.2147/JIR.S401818. eCollection 2023. J Inflamm Res. 2023. PMID: 36855543 Free PMC article. Review.
-
Association between blood groups and myocardial injury after non-cardiac surgery: a retrospective cohort study.Sci Rep. 2024 Jun 18;14(1):14028. doi: 10.1038/s41598-024-61546-w. Sci Rep. 2024. PMID: 38890319 Free PMC article.
References
-
- Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7:678–689. - PubMed
-
- Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170:191–203. - PubMed
-
- Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88–92. - PubMed
-
- Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104:1336–1342. - PubMed
-
- Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491–495. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HHSN268201100007C/HL/NHLBI NIH HHS/United States
- HHSN268201100011I/HL/NHLBI NIH HHS/United States
- R01 HL076784/HL/NHLBI NIH HHS/United States
- R01HL076784/HL/NHLBI NIH HHS/United States
- HHSN268201100006C/HL/NHLBI NIH HHS/United States
- R01 CA047988/CA/NCI NIH HHS/United States
- U19 HL069757/HL/NHLBI NIH HHS/United States
- HHSN268201100007I/HL/NHLBI NIH HHS/United States
- FS/11/28/28758/BHF_/British Heart Foundation/United Kingdom
- R01HL086694/HL/NHLBI NIH HHS/United States
- HHSN268201100012C/HL/NHLBI NIH HHS/United States
- UL1RR025005/RR/NCRR NIH HHS/United States
- N02-HL-6-4278/HL/NHLBI NIH HHS/United States
- N01-HC-25195/HC/NHLBI NIH HHS/United States
- R01HL064753/HL/NHLBI NIH HHS/United States
- HHSN268201100009I/HL/NHLBI NIH HHS/United States
- R01HL59367/HL/NHLBI NIH HHS/United States
- HHSN268201100010C/HL/NHLBI NIH HHS/United States
- UL1 RR025005/RR/NCRR NIH HHS/United States
- HHSN268201100008C/HL/NHLBI NIH HHS/United States
- HL 043851/HL/NHLBI NIH HHS/United States
- HHSN268201100005G/HL/NHLBI NIH HHS/United States
- HL69757/HL/NHLBI NIH HHS/United States
- HHSN268201100008I/HL/NHLBI NIH HHS/United States
- R01 HL043851/HL/NHLBI NIH HHS/United States
- R01AG028321/AG/NIA NIH HHS/United States
- R01 HL059367/HL/NHLBI NIH HHS/United States
- R01 HL064753/HL/NHLBI NIH HHS/United States
- HHSN268201100011C/HL/NHLBI NIH HHS/United States
- R01 HL086694/HL/NHLBI NIH HHS/United States
- RC1 HL101056/HL/NHLBI NIH HHS/United States
- HHSN268200625226C/PHS HHS/United States
- U01 HG004402/HG/NHGRI NIH HHS/United States
- U01HG004402/HG/NHGRI NIH HHS/United States
- CA 047988/CA/NCI NIH HHS/United States
- N01 HC025195/HL/NHLBI NIH HHS/United States
- R01HL087641/HL/NHLBI NIH HHS/United States
- R01 HL102214/HL/NHLBI NIH HHS/United States
- HHSN268201100005I/HL/NHLBI NIH HHS/United States
- HHSN268201100009C/HL/NHLBI NIH HHS/United States
- FS/09/044/28007/BHF_/British Heart Foundation/United Kingdom
- HHSN268201100005C/HL/NHLBI NIH HHS/United States
- R01 AG028321/AG/NIA NIH HHS/United States
- R01 HL087641/HL/NHLBI NIH HHS/United States
- U01 HL069757/HL/NHLBI NIH HHS/United States
- FS/07/021/BHF_/British Heart Foundation/United Kingdom
LinkOut - more resources
Full Text Sources